31st May 2026, Sunday

TechPharus

Latest Posts

HealthTech News

  • Long-term leukemia trial reveals MRD-triggered treatment may slow or prevent relapse
    on May 31, 2026 at 3:30 pm

    With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an important milestone. The results demonstrate the potential of early, minimal residual disease (MRD)-guided therapy to delay or possibly prevent relapses. RELAZA2 is considered the world’s first MRD-triggered prospective study in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The study is published in the journal Blood.

  • One-time gene editing treatment lowers ‘bad’ cholesterol by up to 62%
    on May 31, 2026 at 3:00 pm

    Patients in London have received a pioneering new gene editing therapy that lowers “bad” cholesterol after a single infusion, as part of a study involving UCL scientists.

  • Study highlights major gaps in online info for patients about AI and cancer
    on May 31, 2026 at 2:50 pm

    Online information about artificial intelligence (AI) and its impact on cancer research and treatment for both the patient and general-public audiences is limited, and the available webpages and videos are largely of low quality, difficult to read, and frequently omit risks of AI use, according to new research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and led by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn’s Perelman School of Medicine.

  • New T-cell engager shows promise for advanced solid tumors
    on May 31, 2026 at 2:00 pm

    As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifically links cancer cells with T cells, thereby directly activating the immune system to fight the tumor. To achieve this, the molecule simultaneously binds to two targets: a protein produced in tumor cells known as the tumor antigen MAGEA4/8, and a molecule on the surface of the body’s immune cells (CD3). These immune cells, known as T lymphocytes, are thereby directed specifically to the tumor locations and activated so that they can destroy the cancer cells.

  • Endocannabinoid drop links to severe acute pancreatitis, offering possible treatment target
    on May 31, 2026 at 1:30 pm

    A study led by researchers from the Respiratory and Immune Repair (REPAIR) group at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with researcher Daniel Closa from IIBB-CSIC, Enrique de-Madaria from ISABIAL and CIBEREHD, and researcher Karina Cárdenas-Jaen from Miguel Hernández University, has identified alterations in the endocannabinoid system associated with the most severe forms of acute pancreatitis.